10.6084/m9.figshare.5472751.v1
Robert M.
Robert
M.
Jarlier M.
Jarlier
M.
Gourgou S.
Gourgou
S.
Desseigne F.
Desseigne
F.
Ychou M.
Ychou
M.
Bouché O.
Bouché
O.
Juzyna B.
Juzyna
B.
Conroy T.
Conroy
T.
Bennouna J.
Bennouna
J.
Supplementary Material for: Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4)
Karger Publishers
2017
Metastatic pancreatic cancer
FOLFIRINOX
ca19-9
Biomarkers
2017-10-05 12:29:17
Dataset
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Retrospective_Analysis_of_CA19-9_Decrease_in_Patients_with_Metastatic_Pancreatic_Carcinoma_Treated_with_FOLFIRINOX_or_Gemcitabine_in_a_Randomized_Phase_III_Study_ACCORD11_PRODIGE4_/5472751
<p><b><i>Objectives:</i></b> Carbohydrate antigen 19-9 (CA19-9) is a
sensitive and specific serum marker in pancreatic cancer. Our
retrospective analysis aims to evaluate CA19-9 decrease in patients with
metastatic pancreatic cancer treated in ACCORD11/PRODIGE4 (FOLFIRINOX
vs. gemcitabine). <b><i>Methods:</i></b> A total of 342 patients were
treated. CA19-9 was measured at 8 weeks (±2) in 160 patients from a
total of 282 with abnormal CA19-9 values at baseline (gemcitabine arm, <i>n</i> = 75; FOLFIRINOX arm, <i>n</i>
= 85). In the present study, 8-week CA19-9 decrease or greater CA19-9
decrease according to the 20 and 90% thresholds were analyzed.
Progression-free survival (PFS) and overall survival (OS) were estimated
in each subgroup. <b><i>Results:</i></b> In the FOLFIRINOX arm,
patients with an 8-week CA19-9 decrease or greater CA19-9 decrease ≥20%
showed improved median OS, PFS, and objective response rate. In the
overall study population, median OS and PFS were significantly improved
in patients with an 8-week CA19-9 decrease ≥20% (vs. <20%). The
8-week CA19-9 decrease was predictive of PFS (interaction test
significant according to treatment arm; <i>p</i> = 0.006). <b><i>Conclusion:</i></b>
An 8-week CA19-9 decrease ≥20% is a prognostic factor for OS and PFS.
The 8-week CA19-9 decrease (20% threshold) is predictive of PFS. It
could help to evaluate the efficacy of FOLFIRINOX and gemcitabine
regimens.</p>